Skip to content
NewsBlazeAU – Lifestyle
Author:
BioVie, Inc.
BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026
November 2, 2026
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
October 26, 2026
BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting
October 20, 2026
BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
October 19, 2026
BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
October 14, 2026
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
September 15, 2026
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
September 14, 2026
BioVie Updates Parkinson’s Phase 3 Program, FDA Engagement
September 8, 2026
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
August 6, 2026
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2
May 27, 2026
1
2
Next Page
→